

# CITATION REPORT

List of articles citing

Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C

DOI: 10.1111/bcp.13095

British Journal of Clinical Pharmacology, 2017, 83, 269-293.

**Source:** <https://exaly.com/paper-pdf/67693723/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
60	Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. <i>Clinical Drug Investigation</i> , <b>2017</b> , 37, 635-646	3.2	17
59	Interferon free antiviral treatment of chronic hepatitis C in patients affected by $\beta$ -thalassemia major. <i>Annals of Hematology</i> , <b>2017</b> , 96, 1043-1045	3	7
58	Pharmacokinetic Interactions between Simeprevir and Ledipasvir in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients without Cirrhosis Treated with a Simeprevir-Sofosbuvir-Ledipasvir Regimen. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	5
57	Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C. <i>British Journal of Clinical Pharmacology</i> , <b>2017</b> , 83, 269-293	3.8	54
56	Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials. <i>Therapeutics and Clinical Risk Management</i> , <b>2017</b> , 13, 477-497	2.9	11
55	Direct-Acting Antivirals (DAAs): Drug-Drug Interactions (DDIs) in the Treatment of Hepatitis C Virus (HCV). <b>2017</b> ,		2
54	Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530). <i>Journal of Medicinal Chemistry</i> , <b>2018</b> , 61, 4052-4066	8.3	28
53	Current antiviral drugs and their analysis in biological materials - Part II: Antivirals against hepatitis and HIV viruses. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2018</b> , 147, 378-399	3.5	28
52	Current antiviral drugs and their analysis in biological materials-Part I: Antivirals against respiratory and herpes viruses. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2018</b> , 147, 400-416	3.5	13
51	Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney. <i>Journal of Nephrology</i> , <b>2018</b> , 31, 1-13	4.8	11
50	Potential drug-drug interactions of OMBITASVIR, PARITAPREVR/ritonavir $\oplus$ DASABUVIR $\oplus$ ribavirin in clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2018</b> , 33, 1100-1107	4	5
49	The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. <i>Expert Review of Clinical Pharmacology</i> , <b>2018</b> , 11, 999-1030	3.8	16
48	Relative Activity Factor (RAF)-Based Scaling of Uptake Clearance Mediated by Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 in Human Hepatocytes. <i>Molecular Pharmaceutics</i> , <b>2018</b> , 15, 2277-2288	5.6	24
47	Safety of Direct-Acting Antiviral Therapy Regarding Renal Function in Post-Liver Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response-A Single-Center Study. <i>Transplantation Proceedings</i> , <b>2018</b> , 50, 1444-1450	1.1	3
46	Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects. <i>Pharmacology Research and Perspectives</i> , <b>2018</b> , 6, e00395	3.1	4
45	Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 2112-2119	5.1	11
44	Glycyrrhizin has a high likelihood to be a victim of drug-drug interactions mediated by hepatic organic anion-transporting polypeptide 1B1/1B3. <i>British Journal of Pharmacology</i> , <b>2018</b> , 175, 3486-3503	8.6	11

43	Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUIILT cohort. <i>European Journal of Clinical Pharmacology</i> , <b>2019</b> , 75, 1555-1563	2.8	
42	Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 3046-3057	8.7	69
41	Long-term follow-up of HCV infected kidney transplant recipients receiving direct-acting antiviral agents: a single-center experience in China. <i>BMC Infectious Diseases</i> , <b>2019</b> , 19, 645	4	4
40	Heart and Lung Transplants from HCV-Infected Donors. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 987-988	59.2	1
39	Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients. <i>International Urology and Nephrology</i> , <b>2019</b> , 51, 2295-2304	2.3	3
38	Letter: contraindicated drug-drug interactions before and after initiation of direct-acting anti-viral agents in chronic hepatitis C patients in Taiwan. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 113-115	6.1	1
37	Concerns About Direct-Acting Antiviral Agents for Hepatitis C-Cause for Reassurance. <i>JAMA Network Open</i> , <b>2019</b> , 2, e194757	10.4	3
36	Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain. <i>Gastroenterología Y Hepatología (English Edition)</i> , <b>2019</b> , 42, 465-475	0.1	1
35	Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 53-58	3.2	3
34	Treatment With Grazoprevir/Elbasvir for Renal Transplant Recipients With Chronic Hepatitis C Virus Infection and Impaired Allograft Function. <i>Transplantation Direct</i> , <b>2019</b> , 5, e419	2.3	4
33	A Generic Model for Quantitative Prediction of Interactions Mediated by Efflux Transporters and Cytochromes: Application to P-Glycoprotein and Cytochrome 3A4. <i>Clinical Pharmacokinetics</i> , <b>2019</b> , 58, 503-523	6.2	5
32	Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infection. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 56, 105571	14.3	11
31	The benefits of a public pharmacist service in chronic hepatitis C treatment: The real-life results of sofosbuvir-based therapy. <i>Research in Social and Administrative Pharmacy</i> , <b>2020</b> , 16, 48-53	2.9	2
30	Development and Validation of a New LC-MS/MS Analytical Method for Direct-Acting Antivirals and Its Application in End-Stage Renal Disease Patients. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2020</b> , 45, 89-99	2.7	5
29	Recent advances in preclinical in vitro approaches towards quantitative prediction of hepatic clearance and drug-drug interactions involving organic anion transporting polypeptide (OATP) 1B transporters. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2020</b> , 35, 56-70	2.2	8
28	Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection. <i>Journal of International Medical Research</i> , <b>2020</b> , 48, 300060520964659	1.4	0
27	Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review. <i>Clinical Drug Investigation</i> , <b>2020</b> , 40, 1001-1008	3.3	3
26	2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population. <i>Journal of the Formosan Medical Association</i> , <b>2020</b> , 119, 1019-1040	3.2	27

25	Development and validation of UPLC-MS/MS method for studying the pharmacokinetic interaction of dasabuvir and tamoxifen, 4-hydroxytamoxifen in Wistar rats. <i>Scientific Reports</i> , <b>2020</b> , 10, 3521	4.9	2
24	Influence of drug-drug interactions on effectiveness and safety of direct-acting antivirals against hepatitis C virus. <i>European Journal of Hospital Pharmacy</i> , <b>2021</b> , 28, 16-21	1.6	1
23	Sustained Virologic Response of Patients Hospitalized Compared With Those Not Hospitalized During Treatment for Hepatitis C Virus With Direct-Acting Antivirals. <i>Annals of Pharmacotherapy</i> , <b>2021</b> , 55, 565-574	2.9	
22	Emerging paradigms of viral diseases and paramount role of natural resources as antiviral agents. <i>Science of the Total Environment</i> , <b>2021</b> , 759, 143539	10.2	7
21	Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C. <i>International Journal of General Medicine</i> , <b>2021</b> , 14, 289-301	2.3	6
20	Tuberculosis and pharmacological interactions: A narrative review.. <i>Current Research in Pharmacology and Drug Discovery</i> , <b>2021</b> , 2, 100007	3	2
19	Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature. <i>Current Drug Metabolism</i> , <b>2021</b> , 22, 89-98	3.5	0
18	Asymmetric profiles of infection and innate immunological responses in human iPS cell-derived small intestinal epithelial-like cell monolayers following infection with mammalian reovirus. <i>Virus Research</i> , <b>2021</b> , 296, 198334	6.4	
17	Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2021</b> , 10, 658-670	4.5	1
16	Drug-Drug Interactions in Italian Patients with Chronic Hepatitis C Treated with Pangenotypic Direct Acting Agents: Insights from a Real-World Study. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	0
15	Impact of the COVID-19 Outbreak on the Management of Patients with Cancer. <i>Targeted Oncology</i> , <b>2020</b> , 15, 249-259	5	65
14	Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medications associated with patients with chronic hepatitis C virus infection in Spain. <i>Gastroenterología Y Hepatología</i> , <b>2019</b> , 42, 465-475	0.9	7
13	PK/PD and antiviral activity of anti-HCV therapy: is there still a role in the choice of treatment?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 97-101	5.5	7
12	Prevalence of HCV Infection in Adults with Congenital Heart Disease and Treatment with Direct Antiviral Agents. <i>Southern Medical Journal</i> , <b>2018</b> , 111, 137-141	0.6	2
11	Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens. <i>Oncotarget</i> , <b>2017</b> , 8, 90916-90924	3.3	3
10	Era of direct acting anti-viral agents for the treatment of hepatitis C. <i>World Journal of Hepatology</i> , <b>2018</b> , 10, 670-684	3.4	16
9	Effectiveness and potential drug interactions in antiviral therapy for the treatment of chronic hepatitis C: real-life data from a specialized center in southern Brazil. <i>Brazilian Journal of Pharmaceutical Sciences</i> , 57,	1.8	
8	Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice. <i>Annals of Gastroenterology</i> , <b>2017</b> , 30, 542-549	2.2	2

7	DRUG-FOOD INTERACTION. <i>Bulletin of Problems Biology and Medicine</i> , <b>2019</b> , 1, 10	0.1	
6	Evaluation of the Potency of Anti-HIV and Anti-HCV Drugs to Inhibit P-Glycoprotein Mediated Efflux of Digoxin in Caco-2 Cell Line and Human Precision-Cut Intestinal Slices.. <i>Pharmaceuticals</i> , <b>2022</b> , 15,	5.2	○
5	In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models.. <i>AAPS Journal</i> , <b>2022</b> , 24, 45	3.7	○
4	Drug-drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study.		○
3	Direct antiviral agents (DAAs) and their use in pregnant women with hepatitis C (HCV). 1-12		○
2	TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes. <b>2023</b> , 122, 202-220		○
1	Global treatment rate and barriers to direct-acting antiviral therapy: A systematic review and meta-analysis of 146 studies and 1 760 352 hepatitis C virus patients.		○